GI CANCERS

The FDA approval of Guardant Shield marks the second blood-based diagnostic test for colorectal cancer in those age 45 and older at average risk of the disease.

A new dendritic cell vaccine has shown promising results in extending survival for pancreatic cancer patients by stimulating the immune system to fight tumor cells.

Patrick Boland, MD, discussed the practice-changing implications of the phase 3 ESOPEC study comparing FLOT vs CROSS regimens for the treatment of esophageal adenocarcinoma.

A dendritic cell vaccine called DOC1021 shows early promise in treating pancreatic cancer and has received a fast track designation from the FDA.

The ESOGUARD BE-1 trial demonstrated that the EsoGuard test, combined with EsoCheck, effectively detects esophageal precancer and supports its use as a screening tool to prevent esophageal cancer.

The FDA has received a 505(b)(2) new drug application seeking approval for a lutetium Lu 177 dotatate injection as a potential treatment for SSTR-positive gastroenteropancreatic neuroendocrine tumors.

MRG004A, a novel antibody-drug conjugate, elicited antitumor activity and had manageable toxicities when used in heavily pretreated patients with multiple tumor types with high tissue factor.

Final analysis from KEYNOTE-585 revealed that event-free survival (EFS) was not significantly improved.

Mark A. Lewis, MD, discusses recent data from the COMMIT trial investigating first-line treatment of patients with deficient DNA mismatch repair or microsatellite instability–high metastatic colorectal cancer.

The Oncology Brothers and Mark A. Lewis, MD, review recent updates from the COLLISION study that were presented at the 2024 ASCO Annual Meeting.

Medical oncologists review recent data from the TRANSMET study evaluating chemotherapy plus liver transplantation in patients with unresectable colorectal liver metastases.

Mark A. Lewis, MD, and the Oncology Brothers discuss recent updates from the ARMANI trial in HER2- gastric/ gastroesophageal junction cancer.

Following ASCO 2024, Mark A. Lewis, MD, joins Rahul Gosain, MD, and Rohit Gosain, MD, to provide comprehensive insights on recent updates from the ESOPEC trial in esophageal adenocarcinoma.

Modified FOLFIRINOX with nivolumab in the neoadjuvant setting was associated with favorable rates of R0 resection in patients with borderline resectable pancreatic cancer.

Mark A. Lewis, MD, discusses the exciting progress of dostarlimab in treating rectal cancer.

mKRAS-specific T-cell responses that were produced by ELI-002 7P correlated with tumor biomarker responses among patients with pancreatic and colorectal cancer.

Zanidatamab therapy led to confirmed responses, disease control, and favorable overall survival in pretreated HER2+ biliary tract cancer in an update of the HERIZON-BTC-01 trial.

Perioperative chemotherapy with improved OS vs neoadjuvant chemoradiation in resectable esophageal cancer.

Shubham Pant, MD, discusses background on zanidatamab and findings from the HERIZON-BTC-01 trial of the agent for HER2-positive biliary tract cancer treatment.

Zolbetuximab could become the first CLDN18.2-targeted therapy approved for this patient population in the US.

VCN-01, an adenovirus therapy, received fast track designation from the FDA for treating metastatic pancreatic cancer in combination with standard chemotherapy.

The FDA has withdrawn the approval for infigratinib to treat patients with cholangiocarcinoma. A phase 3 study comparing it to standard treatment has also been halted.

The combination of pembrolizumab, trastuzumab, and chemotherapy showed significant improvement in overall survival vs placebo in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma.

In this episode of Emerging Experts, Michael LaPelusa, MD, shares his insights, experiences, and passion for cancer research, particularly in the realm of gastrointestinal cancers.